Joined Cases C-119/22 and C-149/22, Teva and Others: Judgment of the Court (Third Chamber) of 19 December 2024 (requests for a preliminary ruling from the Markkinaoikeus, Finland, and the Supreme Court, Ireland) – Teva BV, Teva Finland Oy (C-119/22), Merck Sharp & Dohme LLC, formerly Merck Sharp & Dohme Corp. (C-149/22) v Merck Sharp & Dohme LLC, formerly Merck Sharp & Dohme Corp. (C-119/22), Clonmel Healthcare Limited (C-149/22) (Reference for a preliminary ruling – Medicinal products for human use – Supplementary protection certificate (SPC) – Regulation (EC) No 469/2009 – Conditions for obtaining an SPC for medicinal products – Article 3(a) – Concept of product protected by a basic patent in force – Article 3(c) – Concept of product the subject of an SPC – Criteria for assessment)